For peptide microarray-based epitope mappings, an antigen sequence is translated into overlapping peptides. To save costs, the peptide-peptide overlap is frequently reduced to e.g. 10 or 11 amino acids with 15mer peptides, as provided by most commercial suppliers. The peptide-peptide overlap, however, plays an important role for epitope prediction. A reduced peptide-peptide overlap hampers the exact identification of conserved core motifs, the unambiguous itemization of neighbored epitopes in polyclonal samples, or the discrimination of non-specific binders from real epitopes.
Due to our proprietary laser printer-based on-chip synthesis, PEPperPRINT is able to routinely translate antigens into peptide microarrays with a maximum peptide-peptide overlap, e.g. 14 amino acids with 15mer peptides (equals a shift of 1), to provide the maximum amount of epitope coverage and prediction at reasonable costs.

For further information please read the application note “Comparison of High Resolution PEPperMAP® Epitope Mappings with Low Resolution Epitope Mappings” available on the website

PEPperCIP epitope mapping

High resolution linear Epitope Mapping is based on an antigen translated into 15 aa overlapping peptides with maximum peptide-peptide overlap of 14 aa (shift 1). The peptides are directly synthesized on the glass slides. The array is subsequently stained with the target antibody that binds to its specific epitope and a secondary antibody that has a fluorescence label. An image of the array is taken with a microarray scanner. Since PEPperPRINT prints spot duplicates, each signal appears in a double row. After data acquisition, the PepSlide® Analyzer software immediately calculates the common motif in the peptide hits, which is the epitope of the target antibody.
On the left two examples of such an epitope mapping are shown, a monoclonal sample binding to a single epitope and a polyclonal sample binding to multiple epitopes. Each array is surrounded by HA (red) and FLAG (green) control peptides.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy